8-K current report · filed Sep 23, 2026

Theravance Biopharma, Inc. (TBPH) 8-K Current Report: September 23, 2026

Item 1.01Item 3.03Item 5.01Item 5.02Item 8.01Item EX-99.1Item 3.01Item 2.01Item 5.03TBPH overview

Short answer

Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 3.01 (Notice of Delisting), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Item 1.01 contains no standalone agreement terms.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

Theravance Biopharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Item 1.01 contains no standalone agreement terms
  • Material transaction details reside in Items 2.01 and 5.02 of the same filing

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Acquisition completed: TBPH ordinary shares converted into $17.00 cash plus one contingent value right per share
  • CVR consideration remains contingent, payable only if specified conditions and timing requirements are met
  • Vested and unvested options and equity awards canceled, with eligible holders receiving cash based on $17.00 per share plus CVRs
  • Options priced at or above $17.00 received no merger consideration
  • Transaction eliminates existing public equity awards and transfers future contingent value to CVR holders

Item 3.01 · Notice of Delisting

  • TBPH requested Nasdaq trading suspension at close of September 23, 2026 following transaction closing
  • Form 25 filing will delist ordinary shares from Nasdaq, effective 10 days after filing
  • Planned Form 15 filing would terminate Exchange Act registration and suspend ongoing SEC reporting obligations
  • Shareholders should expect loss of Nasdaq liquidity and reduced public disclosure after deregistration

Item 3.03 · Material Modification to Rights of Security Holders

  • Merger completion eliminated existing Ordinary Shareholder rights at the Effective Time
  • Shareholders retained only the right to receive the Per Share Merger Consideration
  • Event represents a material change in ownership rights tied to the merger transaction

Item 5.01 · Changes in Control of Registrant

  • Merger completion triggered a change in control of Theravance Biopharma
  • TBPH became a wholly owned subsidiary of Parent, removing standalone public-company status
  • Parent funded the transaction with cash on hand and new debt financing
  • Transaction details and related governance changes incorporated from Items 2.01, 5.02 and 5.03

Item 5.02 · Departure/Election of Directors or Officers

  • Merger-related leadership turnover: Rick Winningham resigned as CEO, alongside six directors
  • New three-member board: Kristin Stafford, Scott Platshon and Paul Schneider appointed at closing
  • Departures explicitly unrelated to disagreements over operations, policies or practices
  • Susannah Gray retained under a 12-month consultation agreement to negotiate a CVR Product License
  • Gray’s consultation services carry no compensation from Theravance

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Merger-effective governance documents replaced TBPH’s prior charter with the surviving company’s Cayman memorandum and articles
  • Corporate name references changed from “Zymeworks Merger Sub 1” to “Theravance Biopharma, Inc.”
  • Authorized share capital updated to reflect the merger plan, affecting future corporate and equity authorization
  • New indemnification provisions added as required by Section 6.10(b) of the merger agreement

Item 8.01 · Other Events

  • Non-tradeable CVRs tied to ampreloxetine monetization, with no equity, voting or dividend rights
  • Holders receive pro rata 80% of net proceeds from qualifying transactions within 10 years after merger completion
  • First U.S., UK, Spain, France, Germany or Italy commercial sale triggers potential $50 million cash payment
  • Holders receive 10% of qualifying net sales through the later of 10 years, patent expiration or loss of exclusivity
  • Payments remain highly speculative, dependent on future transactions, approval, commercialization and sales performance

Item EX-99.1 · Exhibit EX-99.1

  • Merger consideration includes one nontransferable CVR per ordinary share and eligible equity-award share
  • CVRs provide $0.93 per CVR upon first commercial sale in the United States, United Kingdom, Spain, France, Germany or Italy
  • Holders receive 80% of net license proceeds from ampreloxetine transactions completed within 10 years after closing
  • Holders receive royalties equal to 10% of net ampreloxetine sales during the applicable royalty term
  • Equity-award CVRs become ineligible for payments occurring more than five years after closing under Section 409A restrictions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Theravance Biopharma, Inc. 8-K filings

Get the next TBPH 8-K as it lands

Follow TBPH for push alerts, or ask the research agent what this filing means.